Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is projected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($1.36) per share and revenue of $37.32 million for the quarter.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $10.79 on Tuesday. The company has a market capitalization of $437.07 million, a PE ratio of -2.07 and a beta of 1.39. Keros Therapeutics has a 52-week low of $9.77 and a 52-week high of $73.00. The company has a 50-day simple moving average of $13.02 and a 200 day simple moving average of $40.44.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on KROS shares. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Scotiabank dropped their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday, January 16th. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Wells Fargo & Company boosted their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Finally, HC Wainwright decreased their price objective on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.